Skip to content
Bending the Curve Trial by Trial
?

Platinum compoundsUsed in a few countriesDerivative of an earlier drugNeeds review

Lobaplatin

Also known as D-19466

A platinum complex with a cyclobutane-based carrier ligand and a lactate leaving group, developed by ASTA Medica. A 2003 profile says it was approved in China for leukaemia, breast and small cell lung cancer.

From discovery to approval

  1. 1990 · First described

    A 1990 report characterised D-19466, a platinum complex with a cyclobutane-based carrier ligand, as active against several mouse tumours, including a cisplatin-resistant P388 line, without a nephrotoxic signal on blood urea. A 2003 profile says ASTA Medica (Degussa) developed it.[2][3][4]

  2. No approval is recorded on this site.

How it works

Forms platinum-DNA adducts, mainly cross-links on one strand between neighbouring guanine and guanine, or adenine and guanine, bases. A review also reports that it influences expression of the c-myc gene, which is involved in cell proliferation and apoptosis.[1]

Where it came from and why

A 2003 profile describes second- and third-generation platinum analogues such as lobaplatin as the response to cisplatin's renal, neurological and gastrointestinal toxicity, aiming at reduced toxicity and a better therapeutic index.

Cancers

  • Chronic myelogenous leukaemia

    Listed among the Chinese approved indications in a 2003 profile, which says the product had not yet been launched there.[3]

  • Inoperable metastatic breast cancer

    Listed among the Chinese approved indications in a 2003 profile.[3]

  • Small cell lung cancer

    Listed among the Chinese approved indications in a 2003 profile; a 2026 review lists the same three indications.[3]

Family and partners

Derived from: Cisplatin

Worth knowing

  • A 2003 profile says ASTA Medica discontinued development, Zentaris took it over, and in January 2003 Zentaris and Hainan Tianwang International Pharmaceutical signed a contract for manufacture and marketing in China.[3]
  • A 2001 review reports that phase I trials of three administration schedules found the same dose-limiting toxicity, thrombocytopenia, and similar maximum tolerated doses of 60 mg/m2 every 3 to 4 weeks.[1]
  • A 1990 report found D-19466 cytotoxic in vitro at concentrations comparable to or lower than those of cisplatin and active in vivo against a cisplatin-resistant P388 line.[2]
  • A 2026 review lists lobaplatin as regionally approved in China in 2003.[5]

References

  1. McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001;10(1):119-28. PubMedDOI
  2. Voegeli R, Schumacher W, Engel J, Respondek J, Hilgard P. D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol. 1990;116(5):439-42. PubMedDOI
  3. Lobaplatin: D 19466 [no author listed]. Drugs R D. 2003;4(6):369-72. PubMedDOI
  4. Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs. 1993;46(3):360-377. PubMedDOI
  5. Kamusheva MS, Varbanov HP. Current clinical applications and future developments of platinum-based anticancer drugs. J Biol Inorg Chem. 2026;31(6):469-488. PubMedDOI